Market Overview

Cytokinetics Earnings Outlook


Cytokinetics (NASDAQ: CYTK) announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.

Earnings and Revenue

Sell-side analysts are expecting Cytokinetics's loss per share to be near 70 cents on sales of $6.32 million.

In the same quarter last year, Cytokinetics reported earnings per share of 16 cents per share on revenue of $33.1 million. If the company were to match the consensus estimate when it reports Thursday, EPS would have fallen 537.5 percent. Sales would be down 80.93 percent on a year-over-year basis.

Here's how the Cytokinetics's reported EPS has stacked up against analyst estimates in the past:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.61 -0.59 -0.27 -0.4
EPS Actual -0.6 -0.6 -0.62 0.16


Stock Performance

Over the last 52-week period, shares are down 23.13 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.

Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. The popular rating by analysts on Cytokinetics stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

Cytokinetics' Q4 conference call is scheduled to begin at 4:00 p.m. ET and can be accessed here:


Related Articles (CYTK)

View Comments and Join the Discussion!

Posted-In: Earnings News Previews Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at